MarketCap
CRISPR Therapeutics AG CRSP
$ 50.09
3.3%
Facebook
X
Telegram
CRISPR Therapeutics AG ROA Ratio | CRSP
Annual ROA Ratio CRISPR Therapeutics AG
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -25.67 | -16.34 | -6.89 | -28.99 | 13.72 | -19.08 | 6.27 | -33.74 | -25.19 | -6.73 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.72 | -33.74 | -14.26 |
Quarterly ROA Ratio CRISPR Therapeutics AG
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.07 | -18.46 | -25.29 | -27.06 | -22.96 | -22.03 | -17.15 | -15.66 | -9.98 | -11.55 | -9.69 | -7.27 | -16.21 | -18.25 | -22.25 | -26.77 | -26.97 | -24.06 | 9.67 | 10.77 | 10.04 | 8.32 | -25.47 | -26.61 | -17.9 | 7.54 | 4.29 | 1.48 | -11.11 | -40.09 | -40.1 | -37.93 | -28.15 | -27.13 | -23.57 | -22.68 | -17.77 | -14.3 | -11.95 | -7.74 | -20.39 | -19.1 | -2.45 | -7.7 | -3.98 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.77 | -40.1 | -15.42 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Curis
CRIS
|
-37.97 | $ 0.88 | 3.67 % | $ 11.6 M |  USA |
 |
Cyclerion Therapeutics
CYCN
|
-37.35 | $ 34.99 | 3.77 % | $ 147 M | USA |
 |
Завод ДИОД
DIOD
|
2.66 | - | - | - |  Russia |
 |
CorMedix
CRMD
|
19.74 | $ 5.31 | 1.43 % | $ 383 K | USA |
 |
Novartis AG
NVS
|
12.59 | $ 162.64 | 0.44 % | $ 315 B |  Schweiz |
 |
PDS Biotechnology Corporation
PDSB
|
-24.8 | $ 1.22 | 4.27 % | $ 56.6 M | USA |
 |
Pfizer
PFE
|
3.73 | $ 29.39 | -0.22 % | $ 167 B | USA |
 |
Pharming Group N.V.
PHAR
|
9.69 | $ 12.32 | 0.16 % | $ 8.49 B |  Niderland |
 |
Orgenesis
ORGS
|
-3565.14 | - | -33.86 % | $ 61.2 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-55.1 | $ 53.74 | -3.26 % | $ 6.45 M | USA |
 |
Фармсинтез
LIFE
|
-25.57 | - | - | - | Russia |
 |
Prothena Corporation plc
PRTA
|
-74.69 | $ 7.93 | 0.51 % | $ 427 M | USA |
 |
Codiak BioSciences
CDAK
|
-21.64 | - | -55.98 % | $ 2.15 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-62.87 | $ 10.54 | 7.55 % | $ 1.47 B |  France |
 |
Rocket Pharmaceuticals
RCKT
|
-67.52 | $ 2.38 | -2.05 % | $ 264 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
11.11 | $ 904.69 | 0.2 % | $ 94.6 B | USA |
 |
Replimune Group
REPL
|
-94.44 | $ 21.67 | 8.24 % | $ 2.01 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
-53.39 | $ 9.47 | 4.76 % | $ 445 M | USA |
 |
Royalty Pharma plc
RPRX
|
3.93 | $ 67.31 | -0.39 % | $ 28.9 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-0.04 | $ 111.51 | 6.18 % | $ 7.25 B | USA |
 |
Puma Biotechnology
PBYI
|
14.38 | $ 8.28 | -15.25 % | $ 414 M | USA |
 |
SIGA Technologies
SIGA
|
10.61 | $ 3.12 | 4.55 % | $ 223 M | USA |
 |
Sage Therapeutics
SAGE
|
-73.22 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.19 | - | - | $ 1.62 B |  Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-20.48 | $ 61.62 | -2.21 % | $ 172 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-34.29 | $ 8.41 | 6.73 % | $ 917 M | USA |
 |
Summit Therapeutics
SMMT
|
-143.72 | $ 16.34 | 15.15 % | $ 12.2 B |  Britain |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 1.3 | 1.17 % | $ 131 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-53.88 | $ 9.53 | 1.39 % | $ 826 M | USA |
 |
Sanofi
SNY
|
6.19 | $ 47.06 | 0.32 % | $ 57.4 B | France |
 |
Forma Therapeutics Holdings
FMTX
|
-30.83 | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-5.69 | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
5.72 | - | - | $ 26.6 B |  Irlanda |
 |
Sarepta Therapeutics
SRPT
|
-21.3 | $ 17.8 | 0.68 % | $ 1.78 B | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-36.84 | - | - | $ 121 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-17.85 | $ 2.84 | -3.07 % | $ 1.93 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
0.76 | $ 21.02 | -0.92 % | $ 33.2 B |  Japan |
 |
Tarsus Pharmaceuticals
TARS
|
-11.74 | $ 68.11 | 0.87 % | $ 2.85 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-179.56 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Bio-Techne Corporation
TECH
|
7.03 | $ 72.78 | 0.17 % | $ 11.4 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
3.46 | $ 42.32 | 1.33 % | $ 48.5 B | Israel |
 |
RedHill Biopharma Ltd.
RDHL
|
-45.82 | $ 0.43 | 0.45 % | $ 5.3 B | Israel |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-69.01 | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-19.57 | - | - | $ 411 M | USA |
 |
Shattuck Labs
STTK
|
-53.62 | $ 4.59 | 2.78 % | $ 319 M | USA |
 |
Seelos Therapeutics
SEEL
|
-699.19 | - | -47.76 % | $ 6.27 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.05 | $ 0.28 | -16.14 % | $ 2.2 M | Israel |